Search
Pulmonx Corp
LUNGAdd to Watchlist
2.010USD
+0.010+0.50%
Market hours 09/24, 10:22（ET）
84.90MMarket Cap
LossP/E TTM
About Pulmonx Corp Company
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Pulmonx Corp Profile
Ticker SymbolLUNG
Company namePulmonx Corp
IPO dateOct 01, 2020
CEOFrench (Glendon E)
Number of employees291
Security typeOrdinary Share
Fiscal year-endOct 01
Address700 Chesapeake Dr
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94063
Phone16509342600
Websitehttps://pulmonx.com/
Ticker SymbolLUNG
IPO dateOct 01, 2020
CEOFrench (Glendon E)
Company Executives of Pulmonx Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Srikanth Radhakrishnan
Mr. Srikanth Radhakrishnan
Chief Science and Technology Officer
Chief Science and Technology Officer
316.99K
-4.49%
Mr. Srikanth Radhakrishnan
Mr. Srikanth Radhakrishnan
Chief Science and Technology Officer
Chief Science and Technology Officer
316.99K
-4.49%
Mr. Srikanth Radhakrishnan
Mr. Srikanth Radhakrishnan
Chief Science and Technology Officer
Chief Science and Technology Officer
316.99K
-4.49%
Mr. Geoffrey Beran Rose
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Chief Commercial Officer
300.56K
-2.62%
Mr. Geoffrey Beran Rose
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Chief Commercial Officer
300.56K
-2.62%
Mr. Geoffrey Beran Rose
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Chief Commercial Officer
300.56K
-2.62%
Dr. Derrick Sung, Ph.D.
Dr. Derrick Sung, Ph.D.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
135.32K
-965.29%
Dr. Derrick Sung, Ph.D.
Dr. Derrick Sung, Ph.D.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
135.32K
-965.29%
Dr. Derrick Sung, Ph.D.
Dr. Derrick Sung, Ph.D.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
135.32K
-965.29%
Mr. Daniel P. (Dan) Florin
Mr. Daniel P. (Dan) Florin
Independent Director
Independent Director
96.76K
+41.34%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Srikanth Radhakrishnan
Mr. Srikanth Radhakrishnan
Chief Science and Technology Officer
Chief Science and Technology Officer
316.99K
-4.49%
Mr. Srikanth Radhakrishnan
Mr. Srikanth Radhakrishnan
Chief Science and Technology Officer
Chief Science and Technology Officer
316.99K
-4.49%
Mr. Srikanth Radhakrishnan
Mr. Srikanth Radhakrishnan
Chief Science and Technology Officer
Chief Science and Technology Officer
316.99K
-4.49%
Mr. Geoffrey Beran Rose
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Chief Commercial Officer
300.56K
-2.62%
Mr. Geoffrey Beran Rose
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Chief Commercial Officer
300.56K
-2.62%
Mr. Geoffrey Beran Rose
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Chief Commercial Officer
300.56K
-2.62%
FAQs
Who are the top five shareholders of Pulmonx Corp?
The top five shareholders of Pulmonx Corp are: Mr. Srikanth Radhakrishnan
How many institutions hold shares of Pulmonx Corp (LUNG)?
As of 2026Q1, 287 institutions hold shares of Pulmonx Corp, with a combined market value of approximately 36.92M, accounting for 87.40% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5702976.00.